Suda Pharmaceuticals Share Price and Company Fundamentals



Price
$0.048
Change
-0.001 (-2.041%)
52 week
0.033 - 0.075

Last traded: Last Friday at 6:10 AM

Suda Pharmaceuticals Ltd, a biotechnology company, focuses on the development of therapies to treat human disease in Australia, the United States, and Canada. The company's product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; Sumatriptan, an oral spray formulation for the treatment of migraine headache; and Anagrelide to treat cancer. It has a license and supply agreement with Cann Pharmaceutical Australia Limited to develop an oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug-resistant epilepsy, melanoma, and motion sickness; and collaborative research agreement with Imperial College London. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.

Key Metrics

PE ratio

-

PB ratio

2.53

Dividend yield

Beta

-1.47

Market cap

$23.08M

Enterprise value

$16.44M

Company profile

Primary activitiesDevelopment and commercialisation of pharmaceutical products through new methods of delivery.
Industry / SectorBiotechnology / Healthcare
Websitehttp://sudapharma.com
Mailing address55 Howe Street Level 1 Unit 12 Osborne Park WA 6017 Australia
Phone / Fax61 8 6142 5555 /
Share registryADVANCED SHARE REGISTRY SERVICES

Dividends

Suda Pharmaceuticals does not pay dividends.

Company Executives

As of Sep 2021, following are the company executives and directors listed on Suda Pharmaceuticals.

NameTitleAgeTotal Pay
Dr. Michael BakerCEO, MD, CTO & Director315.46k
Mr. Stephen John CarterConsultant286.4k
Mr. David PhillipsExec. Director193.8k
Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBACompany Sec. & CFO59
Dr. Richard FranklinProject Director & Member of Scientific Advisory Board
Tony MacintyreGM & CTO

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-399.66%

Return on assets

-28.42%

Return on equity

-76.96%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Suda Pharmaceuticals is 23.08M and its enterprise value is 16.44M. The enterprise value to revenue ratio of SUD is 16.61.

Companies similar to Suda Pharmaceuticals (SUD)

Suda Pharmaceuticals (ASX:SUD) Frequently Asked Questions

1. What is Suda Pharmaceuticals's Stock Symbol?

Suda Pharmaceuticals trades on ASX under the ticker symbol "SUD".

2. What is Suda Pharmaceuticals's stock price today?

One share of SUD stock can currently be purchased for approximately $0.048.

3. How can I contact Suda Pharmaceuticals?

Suda Pharmaceuticals's mailing address is 55 Howe Street Level 1 Unit 12 Osborne Park WA 6017 Australia. The company can be reached via phone at 61 8 6142 5555.

4. What is Suda Pharmaceuticals's official website?

The official website of Suda Pharmaceuticals is http://sudapharma.com.

5. Which share registry manages Suda Pharmaceuticals's stock?

Suda Pharmaceuticals's stock is managed by ADVANCED SHARE REGISTRY SERVICES.